SCHEDULE: Fairmount Funds Files Schedule 13D for Oruka Therapeutics

Fairmount Funds Management LLC reports a 19.99% beneficial ownership stake in Oruka Therapeutics following a lock-up agreement.

Summary

• Fairmount Funds Management LLC and its affiliates maintain a 19.99% beneficial ownership stake in Oruka Therapeutics, Inc.
• The filing serves as Amendment No. 5 to the original Schedule 13D, primarily to disclose a new lock-up agreement.
• The reporting persons hold 13,665,080 shares in aggregate, including common stock and shares issuable upon conversion of Series B Preferred Stock.
• The reporting persons did not participate in the recent underwritten public offering that closed on April 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory update confirming the status of a major shareholder following a capital raise.

Positives

• The reporting group maintains a significant, stable long-term investment position of 19.99% in the company.
• The lock-up agreement demonstrates alignment with the company's recent public offering and commitment to market stability for 45 days.

Negatives

• The reporting persons are subject to a 45-day lock-up period, restricting their ability to trade shares during this timeframe.

Risks

• Beneficial ownership is subject to strict limitations (9.99% for Pre-Funded Warrants and 19.99% for Series B Preferred Stock) which may impact liquidity and conversion timing.
• The investment is subject to market volatility and the company's ability to execute its clinical or commercial strategy.

Future Outlook

The reporting persons have entered into a 45-day lock-up agreement starting from the April 30, 2026, underwriting agreement date, indicating no planned sales of securities during this period.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure for institutional investors in the biotechnology sector, reflecting typical lock-up requirements following a public equity offering.

Comparison to Industry Standards

• The 19.99% ownership stake is consistent with major institutional holdings in clinical-stage biotech companies.
• The use of 45-day lock-up agreements is standard practice for significant shareholders during underwritten public offerings to ensure market stability.

Stakeholder Impact

• Shareholders may view the lock-up agreement as a sign of stability for the company's share price in the short term.

Next Steps

• Expiration of the 45-day lock-up agreement following the April 30, 2026, underwriting agreement.

Key Dates

Keywords

Oruka Therapeutics, Fairmount Funds, Schedule 13D, Beneficial Ownership, Lock-up Agreement, Biotech Investment